Cargando…

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment

Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells expressing tumour-associated antigens to induce tumour cell killing. This inherently relies upon a cytotoxic T-cell population that is able to be recruited. In many cancers, immune checkpoints and other immunosuppress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Winston M, Middleton, Mark R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Therapeutic Tolerance
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439528/ https://www.ncbi.nlm.nih.gov/pubmed/37599903 http://dx.doi.org/10.1093/immadv/ltad013

Ejemplares similares

Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration
por: Mansilla, María José, et al.
Publicado: (2023)

Prevention vs treatment of rheumatoid arthritis
por: Klareskog, Lars, et al.
Publicado: (2023)

Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective
por: Sakaguchi, Shimon, et al.
Publicado: (2023)

Leveraging the lymphohematopoietic graft-versus-host reaction (LGVHR) to achieve allograft tolerance and restore self tolerance with minimal toxicity
por: Sykes, Megan
Publicado: (2023)

Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade
por: Tomita, Yusuke, et al.
Publicado: (2016)

Splenocyte Infusion and Whole-Body Irradiation for Induction of Peripheral Tolerance in Porcine Lung Transplantation: Modifications of the Preconditioning Regime for Improved Clinical Feasibility
por: Jansson, Katharina, et al.
Publicado: (2017)

Minor Antigen Vaccine-Sensitized DLI: In Vitro Responses Do Not Predict In Vivo Effects
por: Rosinski, Steven Lawrence, et al.
Publicado: (2016)

NK cells produce high levels of IL‐10 early after allogeneic stem cell transplantation and suppress development of acute GVHD
por: Chan, Yuen Ling Tracey, et al.
Publicado: (2017)

Tissue‐resident mucosal‐associated invariant T (MAIT) cells in the human kidney represent a functionally distinct subset
por: Terpstra, Matty L., et al.
Publicado: (2020)

Plasmacytoid dendritic cells induce tolerance predominantly by cargoing antigen to lymph nodes
por: Kohli, Karan, et al.
Publicado: (2016)

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
por: Osada, T, et al.
Publicado: (2010)

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
por: Faivre, C, et al.
Publicado: (2017)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Optimisation and molecular signalling of apoptosis in sequential cryotherapy and chemotherapy combination in human A549 lung cancer xenografts in SCID mice
por: Forest, V, et al.
Publicado: (2009)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
por: Wang, Peiyin, et al.
Publicado: (2022)

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
por: Azria, D, et al.
Publicado: (2003)

Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma
por: Granda, T G, et al.
Publicado: (2002)

Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach
por: Tkaczyk, C., et al.
Publicado: (2017)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
por: Simão, Diana C., et al.
Publicado: (2023)

Translation and Clinical Development of Bispecific T‐cell Engaging Antibodies for Cancer Treatment
por: Yuraszeck, T, et al.
Publicado: (2017)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges
por: Alhallak, Kinan, et al.
Publicado: (2021)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling
por: Baker, Lauren CJ, et al.
Publicado: (2016)

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
por: Pridgeon, S W, et al.
Publicado: (2011)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment
por: Lu, Jingjing, et al.
Publicado: (2019)

Olmesartan‐based monotherapy vs combination therapy in hypertension: A meta‐analysis based on age and chronic kidney disease status
por: Deedwania, Prakash, et al.
Publicado: (2017)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Irradiance uniformity optimization for a photodynamic therapy treatment device with 3D scanner
por: Wang, Xu, et al.
Publicado: (2021)

How to Optimise the Collection of Patient-Reported Outcomes in the Context of a Specific Disease such as Eating Disorders
por: Schmidt, U.
Publicado: (2022)

Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses
por: Kjeldsen, Sverre E., et al.
Publicado: (2016)

A Bispecific METxMET Antibody–Drug Conjugate with Cleavable Linker Is Processed in Recycling and Late Endosomes
por: Perez Bay, Andres E., et al.
Publicado: (2023)

Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
por: Rudek, Michelle A., et al.
Publicado: (2016)

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
por: Pero, S C, et al.
Publicado: (2007)

The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
por: Yu, Y, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1b2hiqckl73ai8qmehtsg5e02h